Utility of the skin cancer quality of life impact tool (SCQOLIT)

ISRCTN ISRCTN15839666
DOI https://doi.org/10.1186/ISRCTN15839666
ClinicalTrials.gov number NCT02580916
Secondary identifying numbers 20564
Submission date
03/02/2016
Registration date
03/02/2016
Last edited
04/01/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Rubeta Matin
Public

Churchill Hospital
Old Road
Headington
Oxford
OX3 7LJ
United Kingdom

Phone +44 1865 572971
Email rubeta.matin@ouh.nhs.uk

Study information

Study designProspective non-randomised study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleUse of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non­melanoma skin cancers
Study objectivesThe aim of this study is to explore the practicality and value of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) for non-melanoma skin cancer (NMSC) to patients and clinicians in the dermatology clinical setting.
Ethics approval(s)Oxford B Research Ethics Committee, 18/06/2015, ref: 14/SC/1446
Health condition(s) or problem(s) studiedTopic: Cancer, Dermatology; Subtopic: Melanoma, Skin (all Subtopics); Disease: Skin, Dermatology
InterventionThree hundred patients (100 with squamous cell carcinoma, 200 with basal cell carcinoma) identified in Dermatology outpatient clinics will be recruited to complete SCQOLIT questionnaires at baseline (after histological confirmation of NMSC), at 3 months (by postal or face:face) and at 6-9 months (high risk patients only). Structured interviews with twenty patients and focus group work with 10-15 Dermatology staff will establish acceptability of the SCQOLIT and identify any barriers to implementation. Both quantitative and qualitative analyses will be undertaken.
Intervention typeOther
Primary outcome measureAcceptability of SCQOLIT tool as determined by analysis of patients participation rates and qualitative analysis of patient and staff preferences at the end of the study.
Secondary outcome measuresPsychometric properties of SCQOLIT tool are measured at baseline, 3 months and 6-9 months.
Overall study start date01/07/2015
Completion date30/03/2017

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 300; UK Sample Size: 300
Total final enrolment318
Key inclusion criteria1. Aged 18 years or above
2. Participant is willing and able to give informed consent for participation in the study.
3. All patients with a histopathological diagnosis of NMSC (primary or recurrent disease)
4. All treatments used for NMSC will be included in the study; excision, shave excision, curettage and cautery, Mohs micrographic surgery, photodynamic therapy and topical treatments e.g. imiquimod cream
Key exclusion criteria1. Concurrent internal malignancy as this is likely to significantly influence quality of life (QOL)
2. Patients referred on to other specialties for management of their skin cancer e.g. Plastic surgeons / Clinical oncology
3. Other significant dermatological diseases e.g. severe inflammatory or blistering skin conditions as this may influence QOL
4. Inability to consent for themselves
Date of first enrolment01/07/2015
Date of final enrolment30/06/2016

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Churchill Hospital
Old Road
Headington
Oxford
OX3 7LJ
United Kingdom

Sponsor information

Oxford University Hospitals NHS Trust
Hospital/treatment centre

Research & Development Office
Joint Research Office
Block 60
Churchill Hospital
Headington
OX3 7LE
England
United Kingdom

ROR logo "ROR" https://ror.org/03h2bh287

Funders

Funder type

Research council

Medical Research Council
Government organisation / National government
Alternative name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC
Location
United Kingdom
Oxfordshire Health Services Research Committee

No information available

Results and Publications

Intention to publish date30/06/2018
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planResults will be disseminated at national and international Dermatology/Skin Cancer meetings and publishing in a high impact peer reviewed journal.
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Abstract results results presented at ISOQOL in : 01/10/2016 29/04/2019 No No
Abstract results results presented at the 97th Annual Meeting of the British Association of Dermatologists in : 30/11/2017 29/04/2019 No No
Results article results 01/03/2020 04/01/2021 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

04/01/2021: The following changes have been made:
1. Publication reference added.
2. The total final enrolment number has been added from the reference.
29/04/2019: Publication reference added.
16/04/2019: No publications found, verifying study status with principal investigator.
17/03/2016: Internal review.
18/02/2016: Verified study information with principal investigator.